Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM).
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Adalimumab is the active ingredient of these drugs:
Australia Austria Brazil Cyprus France
Austria Ireland Lithuania
Lithuania
Australia
Austria Lithuania
Austria Ireland Lithuania
Ireland
Austria France Germany Ireland Lithuania
Australia Austria Brazil Canada Cyprus
Australia Austria Brazil Cyprus France
Australia Austria Brazil Cyprus France
Austria Cyprus France Germany Ireland
Lithuania
Ireland
Lithuania
Brazil
Germany Ireland Lithuania United Kingdom
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):